Survival analysis of colorectal cancer liver metastases treated
by percutaneous ablation

k 2020

Survival analysis of colorectal cancer liver metastases treated by percutaneous ablation

ROHAN, Tomáš, Tomáš ANDRAŠINA, Peter MATKULČÍK, Jan ZAVADIL, Vlastimil VÁLEK et. al.

Základní údaje

Originální název

Survival analysis of colorectal cancer liver metastases treated by percutaneous ablation

Autoři

ROHAN, Tomáš (203 Česká republika, garant, domácí), Tomáš ANDRAŠINA (703 Slovensko, domácí), Peter MATKULČÍK (703 Slovensko, domácí), Jan ZAVADIL (203 Česká republika, domácí), Vlastimil VÁLEK (203 Česká republika, domácí), Tomáš MIHOK (703 Slovensko, domácí), Michal UHER (203 Česká republika, domácí) a Vlastimil VÁLEK (203 Česká republika, domácí)

Vydání

CIRSE 2020, 2020

Další údaje

Jazyk

angličtina

Typ výsledku

Prezentace na konferencích

Obor

30224 Radiology, nuclear medicine and medical imaging

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Kód RIV

RIV/00216224:14110/20:00116368

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

colorectal cancer; liver metastasis; percutaneous ablation; survival analysis

Štítky

rivok

Příznaky

Mezinárodní význam

Změněno: 8. 9. 2020 17:55, MUDr. Tomáš Rohan, Ph.D.

Anotace

V originále

Purpose:To analyse and identify factors affecting survival of patients with liver metastasis of colorectal cancer treated by percutaneous ablation. Materials and Methods: Patients with colorectal cancer liver metastasis treated by percutaneous ablation in complex oncological centre from 2005 to 2019 were enrolled in the analysis. The endpoints of the study were overall survival since diagnosis, since the diagnosis of liver metastasis and since the first percutaneous ablation of the liver related to size (on postcontrast axial CT scan),number (1,2,3,multiple) and location(subcapsular,near large vessels,other) of liver metastases and subsequent treatment (surgical resection,systemic treatment,transarterial chemoembolisation). Kaplan-Meier,log-rank and mann-whitney test were used for statistical evaluation. Results:156 consecutive patients (61 women,32,6–89,0 years) with 188 liver metastasis (median 1/patient) with a median size 21mm (4–85mm) were initially ablated.Estimated median survival from diagnosis for synchronous metastases was 51.5months, for metachronous 84.5months. Estimated median survival since liver metastasis in metachronous was 52.9months.Estimated survival since the first ablation was 36.6months in metachronous and 34.2months in synchronous metastases, while the metachronous metastasis were significantly greater (22,5 vs 18,0mm, p=0,005) and patients were significantly older (65,2 vs 60,4 years,p=0,03) at ablation time.Liver metastases of 4-15 mm have significantly better survival since diagnosis of metastases and first ablation than metastases over 15 mm (71.4 and 61.5 vs. 51.5 and 28.7months,p=0.02 and <0.001).No significant difference in survival associated with other factors was observed. Conclusion:Based on retrospective analysis of percutaneous ablation of colorectal cancer liver metastases, the most important survival factor was size of the metastasis, with significantly better results in metastasis up to 15 mm.

Návaznosti

MUNI/A/1488/2019, interní kód MU

Název: Význam radiologických intervencí a pokročilých zobrazovacích metod v diagnostice a léčbě onkologických pacientů

Investor: Masarykova univerzita, Význam radiologických intervencí a pokročilých zobrazovacích metod v diagnostice a léčbě onkologických pacientů, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

ROHAN, Tomáš, Tomáš ANDRAŠINA, Peter MATKULČÍK, Jan ZAVADIL, Vlastimil VÁLEK, Tomáš MIHOK, Michal UHER a Vlastimil VÁLEK. Survival analysis of colorectal cancer liver metastases treated by percutaneous ablation. In CIRSE 2020. 2020.

@proceedings{1677878,
   author = {Rohan, Tomáš and Andrašina, Tomáš and Matkulčík, Peter and Zavadil, Jan and Válek, Vlastimil and Mihok, Tomáš and Uher, Michal and Válek, Vlastimil},
   booktitle = {CIRSE 2020},
   keywords = {colorectal cancer; liver metastasis; percutaneous ablation; survival analysis},
   language = {eng},
   title = {Survival analysis of colorectal cancer liver metastases treated by percutaneous ablation},
   year = {2020}
}

TY  - CONF
ID  - 1677878
AU  - Rohan, Tomáš - Andrašina, Tomáš - Matkulčík, Peter - Zavadil, Jan - Válek, Vlastimil - Mihok, Tomáš - Uher, Michal - Válek, Vlastimil
PY  - 2020
TI  - Survival analysis of colorectal cancer liver metastases treated by percutaneous ablation
KW  - colorectal cancer
KW  - liver metastasis
KW  - percutaneous ablation
KW  - survival analysis
N2  - Purpose:To analyse and identify factors affecting survival of patients with liver metastasis of colorectal cancer treated by percutaneous ablation. Materials and Methods: Patients with colorectal cancer liver metastasis treated by percutaneous ablation in complex oncological centre from 2005 to 2019 were enrolled in the analysis. The endpoints of the study were overall survival since diagnosis, since the diagnosis of liver metastasis and since the first percutaneous ablation of the liver related to size (on postcontrast axial CT scan),number (1,2,3,multiple) and location(subcapsular,near large vessels,other) of liver metastases and subsequent treatment (surgical resection,systemic treatment,transarterial chemoembolisation). Kaplan-Meier,log-rank and mann-whitney test were used for statistical evaluation. Results:156 consecutive patients (61 women,32,6–89,0 years) with 188 liver metastasis (median 1/patient) with a median size 21mm (4–85mm) were initially ablated.Estimated median survival from diagnosis for synchronous metastases was 51.5months, for metachronous 84.5months. Estimated median survival since liver metastasis in metachronous was 52.9months.Estimated survival since the first ablation was 36.6months in metachronous and 34.2months in synchronous metastases, while the metachronous metastasis were significantly greater (22,5 vs 18,0mm, p=0,005) and patients were significantly older (65,2 vs 60,4 years,p=0,03) at ablation time.Liver metastases of 4-15 mm have significantly better survival since diagnosis of metastases and first ablation than metastases over 15 mm (71.4 and 61.5 vs. 51.5 and 28.7months,p=0.02 and <0.001).No significant difference in survival associated with other factors was observed. Conclusion:Based on retrospective analysis of percutaneous ablation of colorectal cancer liver metastases, the most important survival factor was size of the metastasis, with significantly better results in metastasis up to 15 mm.
ER  -

Podrobný výpis o publikaci